Results 211 to 220 of about 77,471 (339)

Multi‐regional Organoid Biobank Reveals FAK‐ACSL1‐Driven Doxorubicin‐Resistance and Predictive Biomarkers in Breast Cancer

Advanced Science, Volume 13, Issue 55, 5 October 2026.
This study established a high‐quality organoid biobank derived from 68 tumor sites across 50 Chinese patients, elucidated the drug sensitivity‐based molecular subtyping in breast cancer, and revealed a novel mechanism of drug resistance mediated by the FAK‐ACSL1 pathway.
Hao Xu, Zhijun Qin, Jiapeng Yang, Baoyuan Zhang, Manqing Cao, Peng Wang, Zaiqi Wang, Jinghui Cheng, Lei Wang, Hong Liu, Hui Yang   +10 more
wiley   +1 more source

Correction: Hypoxia and aspirin additively increase intracellular glutamine accumulation in PIK3CA-mutated colorectal cancer cells. [PDF]

Sci Rep
Umezaki N, Boku S, Matsuo Y, Yamamoto T, Satake H, Watanabe M, Hirota K, Sugie T, Sekimoto M.   +8 more
europepmc   +1 more source

PIK3CA NP_006209.2:p.E542G [PDF]

, 2020
openaire   +1 more source

CA9‐Targeted PET Imaging for Noninvasive Discrimination of Clear Cell Renal Cell Carcinoma and Associated Tumor Biological Features

Advanced Science, Volume 13, Issue 56, 9 October 2026.
CA9‐targeted PET imaging could be a noninvasive approach to characterize clear cell renal cell carcinoma and associated tumor biology. PET uptake correlates with tumor CA9 expression and is linked to angiogenic activity, immune remodeling, and metabolic reprogramming.
Kailei Chen, Sixuan Cheng, Jian Shi, Ruijie Liu, Yilong Wu, Xin Zheng, Xinlun Song, Yunxuan Zhang, Lei Liu, Zhihao Wei, Qi Wang, Xinwei Li, Zirui Dong, Yuenan Liu, Hongmei Yang, Xiaoli Lan, Chunxia Qin, Dawei Jiang, Keshan Wang, Xiaoping Zhang   +19 more
wiley   +1 more source

Biomarker testing in advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2 negative breast cancer: expert recommendations. [PDF]

Ther Adv Med Oncol
Reinert T, Alshehri AS, Shafik A, Lin CH, Gomez Abuin G, Gong G, Jung KH, Amat M, Pathmanathan N, Ow SGW, Rivera-Rivera S, Aggarwal S, Luen SJ, Yong Tay TK.   +13 more
europepmc   +1 more source

Serial ctDNA Analysis for Monitoring Molecular Response and Acquired Resistance in Metastatic NSCLC and HR+/HER2‐Negative Breast Cancer: A Real‐World Study

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACT Circulating tumor DNA (ctDNA) is a promising biomarker for disease monitoring, yet evidence of its clinical utility in routine care remains limited. We evaluated the utility of serial ctDNA monitoring using digital PCR (ddPCR) for detecting acquired resistance (AR) and monitoring response in metastatic non‐small cell lung cancer (NSCLC) and ...
Franciele Hinterholz Knebel, Maurício Fernando Silva Almeida Ribeiro, Rudinei Diogo Marques Linck, Isabela Flauzino Ferreira, Cibele Masotti, Rodrigo Saddi, Karina Perez Sacardo, Felipe Sales Nogueira Amorim Canedo, Leandro Jonata Carvalho Oliveira, Daniele Coelho Duarte, Paula Fontes Asprino, Ernande Xavier dos Santos, Elisângela Monteiro Coser, Dimitrios Kleftogiannis, Louise J. Barber, Marco Gerlinger, João Victor Machado Alessi, Andrea Kazumi Shimada, Fernando Costa Santini, Ciro Eduardo de Souza, Olavo Feher, Gilberto de Castro Junior, Frederico Perego Costa, Max Senna Mano, Artur Katz, Anamaria Aranha Camargo, Fabiana Bettoni   +26 more
wiley   +1 more source

Lanreotide, a Somatostatin Analogue, in Advanced Merkel Cell Carcinoma: A Prospective Single‐Arm Phase II Study

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACT Background Merkel Cell Carcinoma (MCC) is a rare, aggressive neuroendocrine and epithelial skin cancer. Somatostatin analogues, such as lanreotide, have shown efficacy in managing other neuroendocrine tumors. Retrospective studies suggest that lanreotide may induce partial response or disease stabilization in patients with advanced MCC.
Julie Charles, Aude Belbezier, Stéphane Mouret, Brigitte Dreno, Stéphane Dalle, Céleste Lebbe, Ewa Hainaut‐Wierzbicka, Andreea Stefan, Julie de Quatrebarbes, Olivier Dereure, Ouidad Zehou, Sandrine Mansard, Alain Dupuy, Caroline Dutriaux, Florent Grange, Caroline Gaudy‐Marqueste, Henri Montaudié, Jean‐Philippe Arnault, Yannick Le Corre, Thibault Kervarrec, Jean‐Louis Quesada, Mahtab Samimi, Marie‐Thérèse Leccia, The Group of Cutaneous Oncology of the French Society of Dermatology   +23 more
wiley   +1 more source

Prevalence and clinical impact of <i>PIK3CA</i> and <i>PTEN</i> alterations from reflex genomic testing of newly diagnosed colorectal cancer: a population-based series. [PDF]

Front Oncol
Kerrin L, Al Haddad O, Reid E, O'Neill JJ, McConnell L, Abladey A, Kelly PJ, James JA, Davidson C, Lee J, Hanna C, Loughrey MB, Catherwood MA, Coyle VM.   +13 more
europepmc   +1 more source

Use of Metronomic Chemotherapy in Hormone Receptor‐Positive/HER2‐Negative Metastatic Breast Cancer: A Retrospective Multicenter Study

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACT Purpose The optimal chemotherapy strategy after progression on cyclin‐dependent kinase 4/6 inhibitors (CDK4/6i) in hormone receptor‐positive/human epidermal growth factor receptor 2‐negative (HR+/HER2−) metastatic breast cancer remains a matter of controversy.
Lara Laini, Deborah Cosentini, Marta Laganà, Salvatore Grisanti, Giulia Scartabellati, Gianluca Fogazzi, Salvatore Strazzeri, Vito Amoroso, Greta Schivardi, Rebecca Pedersini, Alfredo Berruti, Antonella Turla   +11 more
wiley   +1 more source

Triple-Negative Transformation in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: Tissue Versus Liquid Biopsy in Two Cases. [PDF]

JCO Precis Oncol
Abu Naib S, Ellis P, Velicaria E, Hiley C, Patani N, Al-Shamsi H, Wang X, Patil D, Datta V, Mokbel K, Crook T.   +10 more
europepmc   +1 more source